Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M6YW
|
|||
| Former ID |
DIB003027
|
|||
| Drug Name |
GYKI-12743
|
|||
| Synonyms |
GYKI-12743; Gyki 12743; GKYI-12743; 110714-10-8; 2-(3-(Benzo(1,4)dioxan-2-ylmethylamino)-1-propyl)-3(2H)-pyridazinone hydrochloride; 2-{3-[(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)amino]propyl}pyridazin-3(2h)-one hydrochloride(1:1); 133983-22-9; 3(2H)-Pyridazinone, 2-[3-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]propyl]-, hydrochloride (1:1); 3(2H)-Pyridazinone, 2-(3-(((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)amino)propyl)-, monohydrochloride; AC1Q3EJF; AC1L4TO4; SCHEMBL7284667; CTK4B8909; LS-129872
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Discontinued in Phase 1 | [1] | |
| Company |
Gedeon Richter Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H20ClN3O3
|
|||
| Canonical SMILES |
C1C(OC2=CC=CC=C2O1)CNCCCN3C(=O)C=CC=N3.Cl
|
|||
| InChI |
1S/C16H19N3O3.ClH/c20-16-7-3-9-18-19(16)10-4-8-17-11-13-12-21-14-5-1-2-6-15(14)22-13;/h1-3,5-7,9,13,17H,4,8,10-12H2;1H
|
|||
| InChIKey |
WJDFSAOMSJHHCG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 110714-10-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Modulator | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002059) | |||
| REF 2 | GYKI-12743 a new postsynaptic vascular alpha-adrenoceptor antagonist. Acta Physiol Hung. 1991;77(3-4):257-67. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.